This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

This week, we'll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we'll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma